Rodman & Renshaw Reiterates Outperform, $102 Target on Celgene

Rodman & Renshaw reiterates its Outperform rating and $102 target price on Celgene CELG following quarter and year earnings that see the company's business model shift into next gear. Rodman & Renshaw says, "Celgene reported 4Q11 and FY11 earnings this morning, recording fully-diluted non-GAAP EPS of $1.05 for the quarter and $3.79 for full-year 2011. We had estimated $1.10 for 4Q11, and $3.83 FY11. Non-GAAP revenues for the 4Q rose 22% vs. the same period in 2010 to $1,282mm (lower than our estimates of $1,302mm). Non-GAAP net income for the 4Q rose to $473mm, up 39% from 2010, but ~1% higher from 3Q11. We were expecting $494mm, while the street was at $481mm." CELG closed at $72.66 a share on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetReiterationPre-Market OutlookAnalyst RatingsRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!